Cellbion
308430
Company Profile
Business description
Cellbion is a radiopharmaceutical innovation engaged in the development and commercialization of radioligand therapies to address unmet medical needs, focusing on improving patient outcomes and advancing healthcare through groundbreaking research and cutting-edge technology. Its pipeline products targeted indications are Prostate Cancer radiotherapy, Solid Tumors Diagnosis, Multiple Cancer types, and Others.
Contact
103, Daehak-ro
6th Floor
Jongno-gu
Seoul03080
KORT: +82 27433311
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,520.20 | 9.50 | 0.11% |
| CAC 40 | 7,836.79 | 37.04 | -0.47% |
| DAX 40 | 23,527.01 | 111.55 | -0.47% |
| Dow JONES (US) | 42,011.34 | 129.09 | -0.31% |
| FTSE 100 | 8,585.01 | 17.91 | -0.21% |
| HKSE | 23,640.65 | 532.38 | 2.30% |
| NASDAQ | 19,091.64 | 81.55 | 0.43% |
| Nikkei 225 | 38,128.13 | 55.13 | -0.14% |
| NZX 50 Index | 12,779.26 | 7.48 | -0.06% |
| S&P 500 | 5,882.85 | 3.70 | -0.06% |
| S&P/ASX 200 | 8,279.60 | 10.60 | 0.13% |
| SSE Composite Index | 3,403.95 | 29.08 | 0.86% |